Galectin Therapeutics Inc.
DE ˙ DB ˙ US3632252025
1,88 € 0,00 (0,00%)
2026-06-04
DEL PRIS
SecurityDE:PHPN / Galectin Therapeutics Inc.
InstitutionMorgan Stanley
Latest Disclosed Ownership104,405 shares
Latest Disclosed Value $ 291,290
Morgan Stanley reports 62.62% decrease in ownership of PHPN / Galectin Therapeutics Inc.

On May 15, 2026 - Morgan Stanley filed a 13F-HR form disclosing ownership of 104,405 shares of Galectin Therapeutics Inc. (DE:PHPN) valued at $233,867 USD as of March 31, 2026. The entity filed a previous 13F-HR/A on May 27, 2026 disclosing 279,288 shares of Galectin Therapeutics Inc.. This represents a change in shares of -62.62% during the quarter. The current value of the position is $196,281 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 104,405 -174,883 -62.62 291 -74.94 0.0000
2026-05-27 2025-12-31 13F/A-1 GALECTIN THERAPEUTICS COM NEW 363225202 279,288 50,953 22.32 1,162 20.19 0.0001
2026-02-13 2025-12-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 279,288 50,953 1,162 0.0001
2026-05-27 2025-09-30 13F/A-1 GALECTIN THERAPEUTICS COM NEW 363225202 228,335 19,712 9.45 967 119.55 0.0001
2025-11-14 2025-09-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 228,335 19,712 967 0.0001
2025-08-15 2025-06-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 208,623 -36,469 -14.88 440 47.16 0.0000
2025-05-15 2025-03-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 245,092 -44,992 -15.51 299 -20.05 0.0000
2025-05-15 2024-12-31 13F/A-1 GALECTIN THERAPEUTICS COM NEW 363225202 290,084 44,004 17.88 374 -44.67 0.0000
2025-02-14 2024-12-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 290,084 44,004 374 0.0000
2025-05-14 2024-09-30 13F/A-2 GALECTIN THERAPEUTICS COM NEW 363225202 246,080 18,863 8.30 677 31.77 0.0000
2025-02-14 2024-09-30 13F/A-1 GALECTIN THERAPEUTICS COM NEW 363225202 246,080 18,863 677 0.0000
2024-11-14 2024-09-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 246,080 18,863 677 0.0000
2025-05-14 2024-06-30 13F/A-2 GALECTIN THERAPEUTICS COM NEW 363225202 227,217 42,526 23.03 514 16.33 0.0000
2024-10-17 2024-06-30 13F/A-1 GALECTIN THERAPEUTICS COM NEW 363225202 227,217 42,526 514 0.0000
2024-08-14 2024-06-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 227,217 42,526 514 0.0000
2024-10-17 2024-03-31 13F/A-2 GALECTIN THERAPEUTICS COM NEW 363225202 184,691 -456 -0.25 441 43.65 0.0000
2024-08-16 2024-03-31 13F/A-1 GALECTIN THERAPEUTICS COM NEW 363225202 184,691 -456 441 0.0000
2024-05-15 2024-03-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 184,691 -456 441 0.0000
2024-08-16 2023-12-31 13F/A-1 GALECTIN THERAPEUTICS COM NEW 363225202 185,147 388 0.21 307 -13.28 0.0000
2024-02-13 2023-12-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 185,147 388 307 0.0000
2023-11-15 2023-09-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 184,759 -325 -0.18 355 33.08 0.0000
2023-08-14 2023-06-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 185,084 -3,245 -1.72 267 -32.66 0.0000
2023-05-15 2023-03-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 188,329 149,564 385.82 395 818.60 0.0000
2023-02-14 2022-12-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 38,765 1,218 3.24 44 -29.51 0.0000
2022-11-14 2022-09-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 37,547 -21,309 -36.21 61 -20.78 0.0000
2022-10-27 2022-06-30 13F/A-1 GALECTIN THERAPEUTICS COM NEW 363225202 58,856 -4,653 -7.33 77 -24.51 0.0000
2022-08-15 2022-06-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 58,856 -4,653 77 0.0000
2022-10-27 2022-03-31 13F/A-1 GALECTIN THERAPEUTICS COM NEW 363225202 63,509 -29,794 -31.93 102 -47.42 0.0000
2022-05-13 2022-03-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 63,509 -29,794 102 0.0000
2022-02-14 2021-12-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 93,303 43,335 86.73 194 -0.51 0.0000
2021-11-15 2021-09-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 49,968 9,158 22.44 195 48.85 0.0000
2021-08-23 2021-06-30 13F/A-1 GALECTIN THERAPEUTICS COM NEW 363225202 40,810 14,450 54.82 131 129.82 0.0000
2021-08-16 2021-06-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 40,810 14,450 131 0.0000
2021-05-17 2021-03-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 26,360 -27,302 -50.88 57 -52.89 0.0000
2021-02-16 2020-12-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 53,662 22,083 69.93 121 42.35 0.0000
2020-11-13 2020-09-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 31,579 -33,613 -51.56 85 -57.29 0.0000
2020-08-14 2020-06-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 65,192 9,681 17.44 199 82.57 0.0000
2020-05-26 2020-03-31 13F/A-1 GALECTIN THERAPEUTICS COM NEW 363225202 55,511 -108,050 -66.06 109 -76.71 0.0000
2020-05-15 2020-03-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 55,511 -108,050 109 8.3735
2020-02-14 2019-12-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 163,561 86,147 111.28 468 64.79 0.0001
2019-11-14 2019-09-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 77,414 23,769 44.31 284 27.93 0.0001
2019-08-14 2019-06-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 53,645 -5,332 -9.04 222 -26.25 0.0001
2019-05-15 2019-03-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 58,977 -3,228 -5.19 301 41.31 0.0001
2019-02-14 2018-12-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 62,205 4,518 7.83 213 -38.44 0.0001
2019-04-23 2018-09-30 13F/A-2 GALECTIN THERAPEUTICS COM NEW 363225202 57,687 -3,650 -5.95 346 -11.51 0.0001
2018-11-20 2018-09-30 13F/A-1 GALECTIN THERAPEUTICS COM NEW 363225202 57,687 0 346 0.0001
2018-11-14 2018-09-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 57,687 -3,650 346
2019-04-23 2018-06-30 13F/A-1 GALECTIN THERAPEUTICS COM NEW 363225202 61,337 17,077 38.58 391 86.19 0.0001
2018-08-14 2018-06-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 61,337 17,077 391
2019-04-23 2018-03-31 13F/A-1 GALECTIN THERAPEUTICS COM NEW 363225202 44,260 28,092 173.75 210 288.89 0.0001
2018-05-14 2018-03-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 44,260 28,092 210
2019-04-23 2017-12-31 13F/A-1 GALECTIN THERAPEUTICS COM NEW 363225202 16,168 -87,268 -84.37 54 -75.45 0.0000
2018-02-14 2017-12-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 16,168 -87,268 54
2017-11-14 2017-09-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 103,436 -5,052 -4.66 220 -17.60 0.0001
2017-08-11 2017-06-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 108,488 19,005 21.24 267 29.61 0.0001
2017-05-22 2017-03-31 13F/A-1 GALECTIN THERAPEUTICS COM NEW 363225202 89,483 83,020 1,284.54 206 2,842.86 0.0001
2017-05-12 2017-03-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 89,483 206
2017-02-22 2016-12-31 13F/A-1 GALECTIN THERAPEUTICS COM NEW 363225202 6,463 -158 -2.39 7 0.00 0.0000
2017-02-13 2016-12-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 6,463 7
2016-11-10 2016-09-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 6,621 -1,507 -18.54 7 -41.67 0.0000
2016-08-12 2016-06-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 8,128 2,220 37.58 12 50.00 0.0000
2016-05-12 2016-03-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 5,908 -4,589 -43.72 8 -52.94 0.0000
2016-02-09 2015-12-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 10,497 -3,813 -26.65 17 -50.00 0.0000
2016-02-08 2015-09-30 13F/A-1 GALECTIN THERAPEUTICS COM NEW 363225202 14,310 -13,056 -47.71 34 -54.05 0.0000
2015-11-09 2015-09-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 14,310 34
2015-08-12 2015-06-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 27,366 7,422 37.21 74 10.45 0.0000
2015-05-14 2015-03-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 19,944 -80,223 -80.09 67 -80.69 0.0000
2015-02-13 2014-12-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 100,167 74,132 284.74 347 166.92 0.0001
2014-12-16 2014-09-30 13F/A-1 GALECTIN THERAPEUTICS COM NEW 363225202 26,035 -65,911 -71.68 130 -90.76 0.0000
2014-11-14 2014-09-30 13F GALECTIN THERAPEUTICS COM NEW 363225202 26,035 130
2014-05-13 2014-03-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 91,946 74,266 420.06 1,407 883.92 0.0006
2014-02-13 2013-12-31 13F GALECTIN THERAPEUTICS COM NEW 363225202 17,680 3,056 20.90 143 -2.05 0.0001
2013-11-13 2013-09-30 13F GALECTIN THERAPEUTICS INC C COM 363225202 14,624 14,624 146 0.0001
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.